Opportunity
Federal Register #2026-23141
FDA determination on discontinued drug products and ANDA approvals
Buyer
Food and Drug Administration
Posted
November 13, 2026
Identifier
2026-23141
The FDA issued a regulatory determination about discontinued drug products, rather than a request to buy products or services. - Government buyer: U.S. Department of Health and Human Services (HHS), Food and Drug Administration (FDA); no specific office is identified. - Determination: FDA found the listed products were not withdrawn for safety or effectiveness reasons. They remain in the Orange Book’s Discontinued Drug Product List, and FDA may continue approving qualifying ANDAs that reference them, subject to applicable requirements. - Products and application numbers: DIBENZYLINE (NDA 008708); HALDOL (NDA 018701); VIRAZOLE (NDA 018859); VEPESID (NDA 019557); ALTACE (NDA 019901); BUPHENYL (NDA 020572); SONATA (NDA 020859); HECTOROL (NDA 020862); BYETTA (NDA 021773); BROVANA (NDA 021912); RAPAFLO (NDA 022206); INTERMEZZO (NDA 022328); DEXAMETHASONE SODIUM PHOSPHATE (ANDA 087440); FLUOXETINE HYDROCHLORIDE (NDA 205596); NOXAFIL (NDA 211996); VYNDAQEL (NDA 202133); and AK-FLUOR 25% (NDA 022186). These are application identifiers, not purchase part numbers; no purchase quantities are specified. - Named applicants: Advanz Pharma (US); Janssen Pharmaceuticals, Inc.; Bausch Health US, LLC; Onesource Specialty Private Limited; King Pharmaceuticals LLC; Horizon Therapeutics US Holding LLC; Pfizer, Inc.; Sanofi Genzyme; AstraZeneca AB; Lupin, Inc.; Abbvie, Inc.; Purdue Pharma Products LP; Luitpold Pharmaceuticals, Inc.; TWI Pharmaceuticals, Inc.; Merck Sharp and Dohme Corp.; Foldrx Pharmaceuticals, LLC (a wholly owned subsidiary of Pfizer, Inc.); and Long Grove Pharmaceuticals, LLC. The notice identifies these companies as applicants, not necessarily as physical manufacturers. - Procurement relevance: No products or services are being solicited for purchase, and no contract value or performance period is provided.
Description
The FDA determined that the drug products listed in the notice were not withdrawn from sale for reasons of safety or effectiveness. As a result, FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to those products. Existing ANDAs remain unaffected, and FDA may continue to approve additional ANDAs that meet applicable legal and regulatory requirements.